Reviewing Avantor (NYSE:AVTR) & Bullfrog AI (NASDAQ:BFRG)

Bullfrog AI (NASDAQ:BFRG) and Avantor (NYSE:AVTR) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation and analyst recommendations.

Profitability

This table compares Bullfrog AI and Avantor’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bullfrog AI	N/A	-150.36%	-127.98%
Avantor	5.08%	9.79%	4.74%

Institutional and Insider Ownership

1.0% of Bullfrog AI shares are held by institutional investors. Comparatively, 95.1% of Avantor shares are held by institutional investors. 14.7% of Bullfrog AI shares are held by insiders. Comparatively, 0.3% of Avantor shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk and Volatility

Bullfrog AI has a beta of -2.6, suggesting that its stock price is 360% less volatile than the S&P 500. Comparatively, Avantor has a beta of 0.95, suggesting that its stock price is 5% less volatile than the S&P 500.

Valuation and Earnings

This table compares Bullfrog AI and Avantor”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bullfrog AI	$298,798.00	32.15	-$6.50 million	($0.46)	-1.13
Avantor	$6.64 billion	1.58	-$530.20 million	$0.50	30.98

Bullfrog AI has higher earnings, but lower revenue than Avantor. Bullfrog AI is trading at a lower price-to-earnings ratio than Avantor, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations and price targets for Bullfrog AI and Avantor, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bullfrog AI	1	1	0	0	1.50
Avantor	1	13	2	0	2.06

Avantor has a consensus price target of $14.77, indicating a potential downside of 4.66%. Given Avantor’s stronger consensus rating and higher probable upside, analysts plainly believe Avantor is more favorable than Bullfrog AI.

Summary

Avantor beats Bullfrog AI on 11 of the 14 factors compared between the two stocks.

About Bullfrog AI

Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.

About Avantor

Avantor, Inc. engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, clinical, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Further, it provides scientific research support services, such as DNA extraction, bioreactor servicing, clinical and biorepository, and compound management services. The company was founded in 1904 and is headquartered in Radnor, Pennsylvania.